---
document_datetime: 2024-10-11 12:57:24
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/abevmy-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: abevmy-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.8079094
conversion_datetime: 2025-12-19 01:24:37.637069
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Abevmy

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0025              | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                | 10/10/2024                          |                                             | SmPC                             |           |
| IAIN/0024/G          | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a | 28/05/2024                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                            |            |            |                        | manufacturing   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------|
| IB/0023/G | This was an application for a group of variations. B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product | 27/05/2024 | n/a        |                        |                 |
| IB/0022   | B.II.f.1.a.1 - Stability of FP - Reduction of the shelf life of the finished product - As packaged for sale                                                                                                                                                                                                                                 | 31/01/2024 |            | SmPC                   |                 |
|           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                      | 29/11/2023 |            | Annex II and PL        | IAIN/0021       |
| T/0019    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                         | 03/08/2023 | 30/08/2023 | SmPC, Labelling and PL |                 |
| IB/0018   | B.I.b.2.a - Change in test procedure for AS or                                                                                                                                                                                                                                                                                              | 20/07/2023 | n/a        |                        |                 |

<div style=\"page-break-after: always\"></div>

|                   | starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |             |                                                                                                                                          |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0017           | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 03/02/2023 | n/a        |             |                                                                                                                                          |
| PSUSA/403/2 02202 | Periodic Safety Update EU Single assessment - bevacizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 13/10/2022 | 09/12/2022 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/403/202202. |
| IB/0016           | B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)                                                                                                                                                                                                                                                                                                                                                                                                                     | 06/12/2022 | n/a        |             |                                                                                                                                          |
| IB/0015/G         | This was an application for a group of variations. B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.3.c - Change in test procedure for the immediate packaging of the finished product - | 06/10/2022 | n/a        |             |                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Deletion of a test procedure procedure is already authorised B.II.e.2.z - Change in and/or limits of the immediate finished product - Other B.II.e.2.a - Change in and/or limits of the immediate finished product - Tightening B.III.2.b - Change to comply national pharmacopoeia to comply with an update of the Ph. Eur. or national Member State B.II.e.3.c - Change in immediate packaging of Deletion of a test procedure procedure is already authorised B.II.e.2.c - Change in and/or limits of the immediate finished product - Deletion specification parameter parameter) B.II.e.2.c - Change in and/or limits of the immediate finished product - Deletion specification parameter parameter) B.II.e.2.c - Change in and/or limits of the immediate finished product - Deletion specification parameter   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.II.e.7.a - Change in supplier components or devices dossier) - Deletion of a B.III.2.b - Change to comply national pharmacopoeia to comply with an update of the Ph. Eur. or national Member State B.II.e.2.z - Change in the and/or limits of the immediate finished product - Other B.II.e.2.b - Change in the and/or limits of the immediate finished product - Addition parameter to the specification test method B.III.2.b - Change to comply national pharmacopoeia to comply with an update of the Ph. Eur. or national Member State B.III.2.b - Change to comply national pharmacopoeia to comply with an update of the Ph. Eur. or national Member State B.III.2.b - Change to comply national pharmacopoeia to comply with an update of the Ph. Eur. or national Member State   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | Finished Product - Other variation B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.3.c - Change in test procedure for the immediate packaging of the finished product - Deletion of a test procedure if an alternative test procedure is already authorised B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a   |            |            |             |                                                                                                                                                                                                                |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0014 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 23/08/2022 | 09/12/2022 | SmPC and PL | Sections 4.2 and 6.6 of the SmPC have been updated to add the wording 'Do not shake vial' following reinstatement of the same wording in the PI of the reference product. The PL has been updated accordingly. |

<div style=\"page-break-after: always\"></div>

| IB/0013/G   | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                                 | 26/07/2022   | n/a        |             | procedure                   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-----------------------------|
| IB/0011     | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                          | 19/07/2022   | n/a        |             |                             |
|             | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                        | 20/06/2022   | n/a        |             | IAIN/0012                   |
| IB/0008     | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                 | 11/04/2022   | 09/12/2022 | SmPC and PL |                             |
|             | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure A.4 - Administrative change - Change in the name a manufacturer or an ASMF holder | 18/02/2022   | 09/12/2022 | Annex II    | IA/0007/G and/or address of |

<div style=\"page-break-after: always\"></div>

|           | supplier of the AS, starting material, reagent or used in the manufacture of the AS or of a novel excipient                                                                                                                                                         |            |            |             | or intermediate manufacturer   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------|
| II/0005/G | This was an application for a group of variations. B.II.g.2 - Introduction of a post approval change management protocol related to the finished product B.I.e.2 - Introduction of a post approval change management protocol related to the AS                     | 13/01/2022 | n/a        |             |                                |
| IB/0006   | B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)                                                                                                               | 08/12/2021 | 09/12/2022 | SmPC and PL |                                |
| IB/0004   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                        | 03/08/2021 | n/a        |             |                                |
| IB/0003/G | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation | 30/07/2021 | n/a        |             |                                |
| IB/0001   | B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which                                                                                                                      | 29/07/2021 | n/a        |             |                                |

<div style=\"page-break-after: always\"></div>

| does not have a significant effect on the overall   |
|-----------------------------------------------------|
| quality of the AS                                   |